Literature DB >> 25469037

Azathioprine does not reduce adenoma formation in a mouse model of sporadic intestinal tumorigenesis.

Mattheus C B Wielenga1, Jooske F van Lidth de Jeude1, Sanne L Rosekrans1, Alon D Levin1, Monique Schukking1, Geert R A M D'Haens1, Jarom Heijmans1, Marnix Jansen1, Vanesa Muncan1, Gijs R van den Brink1.   

Abstract

AIM: To investigate if azathioprine could reduce adenoma formation in Apc(Min/+) , a mouse model of sporadic intestinal tumorigenesis.
METHODS: Azathioprine was administered via drinking water (estimated 6-20 mg/kg body weight per day) to Apc(Min/+) and wildtype mice. Control animals received vehicle only (DMSO) dissolved in drinking water. At 15 wk of age all mice were sacrificed and intestines of Apc(Min/+) were harvested for evaluation of polyp number. Azathioprine induced toxicity was investigated by immunohistochemical analysis on spleens.
RESULTS: All azathioprine treated mice showed signs of drug-associated toxicity such as weight loss and development of splenic T-cell lymphomas. Although this suggests that the thiopurine concentration was clearly in the therapeutic range, it did not reduce tumor formation (48 ± 3.1 adenomas vs 59 ± 5.7 adenomas, P = 0.148).
CONCLUSION: We conclude that in the absence of inflammation, azathioprine does not affect intestinal tumorigenesis.

Entities:  

Keywords:  ApcMin; Azathioprine; Chemoprevention; Colon cancer; Intestinal adenoma; Lymphoma; Polyp; Thiopurine

Mesh:

Substances:

Year:  2014        PMID: 25469037      PMCID: PMC4248212          DOI: 10.3748/wjg.v20.i44.16683

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma.

Authors:  J D Lewis; J S Schwartz; G R Lichtenstein
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

Review 2.  Familial colorectal cancer, beyond Lynch syndrome.

Authors:  Elena M Stoffel; Fay Kastrinos
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-17       Impact factor: 11.382

Review 3.  Recent advances: Personalised use of current Crohn's disease therapeutic options.

Authors:  Séverine Vermeire; Marc Ferrante; Paul Rutgeerts
Journal:  Gut       Date:  2013-10       Impact factor: 23.059

Review 4.  The on-off relationship of Rho and Rac during integrin-mediated adhesion and cell migration.

Authors:  Campbell D Lawson; Keith Burridge
Journal:  Small GTPases       Date:  2014-03-07

5.  Association of thiopurine methyltransferase status with azathioprine side effects in Chinese patients with systemic lupus erythematosus.

Authors:  Dongying Chen; Fan Lian; Shiwen Yuan; Yixi Wang; Zhongping Zhan; Yujin Ye; Qian Qiu; Hanshi Xu; Liuqin Liang; Xiuyan Yang
Journal:  Clin Rheumatol       Date:  2013-12-10       Impact factor: 2.980

6.  Oestrogens promote tumorigenesis in a mouse model for colitis-associated cancer.

Authors:  Jarom Heijmans; Mattheus C B Wielenga; Sanne Liesbeth Rosekrans; Jooske F van Lidth de Jeude; Joris Roelofs; Patrick Groothuis; Antwan Ederveen; Eveline S M de Jonge-Muller; Izak Biemond; James C H Hardwick; Geert D'Haens; Daniel W Hommes; Vanesa Muncan; Gijs R van den Brink
Journal:  Gut       Date:  2013-02-13       Impact factor: 23.059

7.  Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.

Authors:  Nabeel Khan; Ali M Abbas; Gary R Lichtenstein; Edward V Loftus; Lydia A Bazzano
Journal:  Gastroenterology       Date:  2013-07-25       Impact factor: 22.682

8.  Is there a risk for lymphoma or extracolonic cancer in patients with inflammatory bowel disease?

Authors:  Elena Toader; Irina Ciortescu
Journal:  Rev Med Chir Soc Med Nat Iasi       Date:  2013 Apr-Jun

9.  Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients.

Authors:  Ana Teresa P Carvalho; Barbara C Esberard; Renata S B Fróes; Davy C M Rapozo; Ana B Grinman; Tatiana A Simão; Juliana C V C Santos; Antonio José V Carneiro; Luis Felipe Ribeiro-Pinto; Heitor S P de Souza
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

10.  Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.

Authors:  Liene Elsone; Joanna Kitley; Sebastian Luppe; Daniel Lythgoe; Kerry Mutch; Saiju Jacob; Rachel Brown; Kathryn Moss; Benjamin McNeillis; Yee Yen Goh; M Isabel Leite; Neil Robertson; Jackie Palace; Anu Jacob
Journal:  Mult Scler       Date:  2014-03-19       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.